ELOTUZUMAB PLUS POMALIDOMIDE/DEXAMETHASONE (EPD) VS PD FOR TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM THE PHASE 2, RANDOMIZED OPEN-LABEL ELOQUENT-3 STUDY
EHA Library, Meletios Dimopoulos, 218888
CLONAL HEMATOPOIESIS: LONG-TERM FOLLOW-UP IN DONORS AND RECIPIENTS OF RELATED ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
EHA Library, Steffen Boettcher, 218887
THE SETBP1 ONCOGENE INDUCES TRANSCRIPTION OF A NETWORK OF DEVELOPMENT GENES BY ACTING AS AN EPIGENETIC HUB
EHA Library, Rocco Piazza, 218886
RESULTS FROM A PHASE 3, MULTICENTER, NONINFERIORITY STUDY OF RAVULIZUMAB (ALXN1210) VERSUS ECULIZUMAB IN ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) NAIVE TO COMPLEMENT INHIBITORS
EHA Library, Jong Wook Lee, 218885
From epidemiology to treatment decisions (the role of T cell registries)
EHA Library, Massimo Federico, 219234
NK/T cell lymphoma: Novel insights, novel therapies?
EHA Library, Won Seog Kim, 219236
PTCL: Evidence for subtype specific treatment approaches?
EHA Library, F D'Amore, 219235
CLONAL HEMATOPOIESIS: LONG-TERM FOLLOW-UP IN DONORS AND RECIPIENTS OF RELATED ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
EHA Library, Steffen BOETTCHER, 219223
HALF OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS RELAPSING UNDER IBRUTINIB CARRY BTK AND PLCG2 MUTATIONS: A EUROPEAN RESEARCH INITIATIVE ON CLL (ERIC) REAL-WORLD STUDY
EHA Library, Lydia Scarfò, 218883
HALF OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS RELAPSING UNDER IBRUTINIB CARRY BTK AND PLCG2 MUTATIONS: A EUROPEAN RESEARCH INITIATIVE ON CLL (ERIC) REAL-WORLD STUDY
EHA Library, Lydia Scarfò, 219219
MAPPING THE THREE-DIMENSIONAL GENOME DYNAMICS IN NORMAL AND NEOPLASTIC B CELLS
EHA Library, Iñaki Martin-Subero, 219220
RESULTS FROM A PHASE 3, MULTICENTER, NONINFERIORITY STUDY OF RAVULIZUMAB (ALXN1210) VERSUS ECULIZUMAB IN ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) NAIVE TO COMPLEMENT INHIBITORS
EHA Library, Jong Wook Lee, 219221
THE SETBP1 ONCOGENE INDUCES TRANSCRIPTION OF A NETWORK OF DEVELOPMENT GENES BY ACTING AS AN EPIGENETIC HUB
EHA Library, Rocco Piazza, 219222
ELOTUZUMAB PLUS POMALIDOMIDE/DEXAMETHASONE (EPD) VS PD FOR TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM THE PHASE 2, RANDOMIZED OPEN-LABEL ELOQUENT-3 STUDY
EHA Library, Meletios Dimopoulos, 219224
Mechanisms underlying oncogenic transcription factors in ALL
EHA Library, Jan Cools, 219226
Novel genetic subgroups in acute lymphoblastic leukemia
EHA Library, Christine Harrison, 219227
Current concepts in ALL frontline trials in children and young adults
EHA Library, Mats Heyman, 219228
Single cell genomics in CML
EHA Library, Adam Mead, 219230
Immune targeting of CML to improve treatment outcome
EHA Library, Andreas Burchert, 219231
TFR treatment goal for all CML patients
EHA Library, Delphine Rea, 219232
Modified FVIII and FIX recombinant products
EHA Library, Elena Santagostino, 219240
Monoclonal antibody-based therapies
EHA Library, Midori Shima, 219239
Future prospects for the treatment of hemophilia: A global perspective
EHA Library, David Lillicrap, 219238
Treating thalassemia with iron restriction
EHA Library, Stefano Rivella, 223400
Is getting old bad?
EHA Library, Michael Heuser, 223399
CAR -T cell therapy: Here to say?
EHA Library, Peter Borchmann, 223398
The best treatment for SAA?
EHA Library, Jakob R Passweg, 223397
Anemia in the elderly: is it real?
EHA Library, Domenico Girelli, 223396
Iron Metabolism: what do you need to know?
EHA Library, Tomas Ganz, 223395
Marginal Zone Lymphona: from diagnosis to treatment
EHA Library, Catherine Thieblemont, 223394
Aspergillus resistance: Time to change the antifungal approach?
EHA Library, Katrien Lagrou, 219215
Assessing MRD in multiple myeloma
EHA Library, Hervé Avet-Loiseau, 219212
How I manage extramedullary disease and plasma cell leukemia
EHA Library, María-Victoria Mateos, 219203
What are the treatment goals and optimal endpoints in RRMM
EHA Library, Thierry Facon, 219202
Which are the preferred treatment combinations and sequence(s): In the transplant eligible / In the elderly
EHA Library, Hartmut Goldschmidt, 219201
Stem cell transplantation for myelofibrosis
EHA Library, Nicolaus Kröger, 219200
Inflammation and anti-inflammatory approaches in MPN
EHA Library, Steffen Koschmieder, 219199
Microenvironment in MPN
EHA Library, Simón Méndez-Ferrer, 219198
Impact of underlying disease on secondary leukemia
EHA Library, Lene Sofie Granfeldt Østgård, 219206
Prognostic factors and treatment options in secondary leukemia
EHA Library, Maria Teresa Voso, 219207
Precision hematology: Implementing genomic profiling at national level
EHA Library, Richard Rosenquist Brandell, 219209
Towards a molecular classification of Philadelphia- negative myeloproliferative neoplasms
EHA Library, Radek Skoda, 219210
Molecular characterization as a basis for novel treatment paradigms in AML
EHA Library, Hartmut Döhner, 219211
Biology of secondary leukemia
EHA Library, Timothy Graubert, 219205
One size does not fit all: Improving outcomes with personalized infection management?
EHA Library, Martin Hoenigl, 219216
New immunomodulators - New infectious diseases mind set?
EHA Library, Sibylle Mellinghoff, 219214
PRECLINICAL EVALUATION OF THE NEW BCMAXCD3 BISPECIFIC ANTIBODY JNJ-957 FOR THE TREATMENT OF MULTIPLE MYELOMA
EHA Library, Kristine Frerichs, 214621
THE MUTATIONAL LANDSCAPE IN HYDROXYCARBAMIDE-RESISTANT/INTOLERANT ESSENTIAL THROMBOCYTHEMIA TREATED ON THE MAJIC-ET STUDY
EHA Library, Jennifer O'Sullivan, 214619
OUTCOMES OF PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH PRIOR BLINATUMOMAB IN ZUMA-3, A STUDY OF KTE-C19, AN ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY
EHA Library, Olalekan O. Oluwole, 214484
GENOMIC ALTERATIONS IN HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA FREQUENTLY AFFECT CELL CYCLE KEY REGULATORS AND NOTCH1 REGULATED TRANSCRIPTION.
EHA Library, Jennifer Edelmann, 214583
TP53 MUTATION HAD A NEGATIVE PROGNOSTIC IMPACT IN UNTREATED YOUNG PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA AT HIGH-RISK: A SUB-ANALYSIS OF FIL-DLCL04 STUDY
EHA Library, Annalisa Chiappella, 214569
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF DARBEPOETIN ALFA FOR THE TREATMENT OF ANEMIC PATIENTS WITH LOW OR INTERMEDIATE-1 RISK MYELODYSPLASTIC SYNDROME
EHA Library, Esther Natalie Oliva, 214478
SINGLE-CELL PROFILING REVEALS KEY DIFFERENCES IN THE CELLULAR ARCHITECTURE OF HUMAN HAEMATOPOIETIC STEM AND PROGENITOR CELLS THROUGHOUT FETAL AND ADULT LIFE
EHA Library, Anindita Roy, 214591
NOVEL INSIGHTS INTO SPLEEN INJURY DURING THE FIRST 2 YEARS OF LIFE IN SCA CHILDREN: A LONGITUDINAL STUDY
EHA Library, Sara El Hoss, 214590
THE FREQUENCY OF THE ETHNIC NEUTROPENIA-ASSOCIATED RS2814778 SNP OF DUFFY ANTIGEN RECEPTOR FOR CHEMOKINES (DARC) GENE IN A COHORT OF EUROPEAN PATIENTS WITH CHRONIC IDIOPATHIC NEUTROPENIA
EHA Library, Helen Papadaki, 214588
CHEMOTHERAPY AND VENETOCLAX IN ELDERLY AML TRIAL (CAVEAT): A PHASE 1B DOSE ESCALATION STUDY EXAMINING MODIFIED INTENSIVE CHEMOTHERAPY IN FIT ELDERLY PATIENTS
EHA Library, Andrew H. Wei, 214491
GENOME WIDE ASSOCIATION STUDIES (GWAS) OF CEREBROVASCULAR EVENTS IN PATIENTS WITH SICKLE CELL ANAEMIA (SCA)
EHA Library, John Brewin, 214626
PERIVASCULAR NICHE CELLS SENSE THROMBOCYTOPENIA AND ACTIVATE PLATELET-BIASED HSCS IN AN IL-1 DEPENDENT MANNER
EHA Library, Tiago Cunha Luis, 214499
PROGNOSTIC FACTORS FOR HLH IN ADULTS – ANALYSIS FROM THE PALG HLH IN ADULTS DATABASE
EHA Library, Rafal Machowicz, 214623
DURABLE RESPONSE WITH VENETOCLAX IN COMBINATION WITH DECITABINE OR AZACITADINE IN ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML)
EHA Library, Courtney D. DiNardo, 214482
PERSISTENT BCR-ABL1 CLONAL HEMATOPOIESIS AFTER BLAST CLEARANCE IDENTIFIES A CML-LIKE SUBGROUP OF PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH+) ALL: INTERIM RESULTS FROM THE GRAAPH-2014 TRIAL
EHA Library, Emmanuelle Clappier, 214483
GROWTH DYNAMICS IN NATURALLY PROGRESSING CHRONIC LYMPHOCYTIC LEUKEMIA
EHA Library, Michaela Gruber, 214582
PHASE 1B/2 COMBINATION STUDY OF APR-246 AND AZACITIDINE (AZA) IN PATIENTS WITH TP53 MUTANT MYELODYSPLASTIC SYNDROMES (MDS) AND ACUTE MYELOID LEUKEMIA (AML)
EHA Library, David Sallman, 214477
FAVOURABLE OUTCOMES WITH R-CODOX-M/R-IVAC ACROSS ALL SUBGROUPS OF AGGRESSIVE HIGH GRADE B-CELL LYMPHOMA: PATHOLOGY AND UPDATED SURVIVAL RESULTS FROM A PHASE 2 UK NCRI/LLR TRIAL
EHA Library, Elizabeth PHILLIPS, 214487
THE COMBINATION OF THE MDM2 ANTAGONIST, IDASANUTLIN WITH NILOTINIB TARGETS PRIMITIVE CHRONIC MYELOID LEUKEMIA (CML) CELLS IN VITRO AND IN VIVO.
EHA Library, Mary Scott, 214573
SIMULTANEOUS TARGETING OF MCL-1 (S63845) AND BCL-2 (VENETOCLAX) ANTI-APOPTOTIC PROTEINS IN MULTIPLE MYELOMA
EHA Library, Esperanza Algarín, 214498
INTEGRATED ATAC-SEQ AND SINGLE-CELL SYNERGISTIC CHEMOSENSITIVITY PROFILING IDENTIFIES RATIONAL DRUG COMBINATIONS IN IBRUTINIB-TREATED CLL PATIENTS
EHA Library, Gregory Vladimer, 214638
IMETELSTAT IN RBC TRANSFUSION-DEPENDENT (TD) LOWER RISK MDS RELAPSED/REFRACTORY TO ERYTHROPOIESIS-STIMULATING AGENTS (ESA) (IMERGE): UPDATED EFFICACY AND SAFETY
EHA Library, Pierre Fenaux, 214476
OVEREXPRESSION OF THE TRANSCRIPTION FACTOR CDX2 IN HAEMATOPOIETIC STEM CELLS PREDISPOSES TO HAEMATOLOGICAL MALIGNANCIES
EHA Library, Therese Vu, 214629
IMPACT OF CONCURRENT FOLLICULAR LYMPHOMA OR OTHER LOW-GRADE B-CELL LYMPHOMA ON THE CLINICAL OUTCOME OF DIFFUSE LARGE B-CELL LYMPHOMA
EHA Library, Yucai Wang, 214618
1 INTRAVASCULAR HEMOLYSIS INDUCES COMPLEMENT SYSTEM ACTIVATION MEDIATED BY HEME AND HEME-LOADED ERYTHROCYTE MICROVESICLES
EHA Library, Lubka Roumenina, 214589
MANAGEMENT OF ELANE-NEUTROPENIA: LIFETIME G-CSF VS HAEMATOPOIETIC STEM CELL TRANSPLANTATION LEARNING LESSON FROM THE EXPERIENCE
EHA Library, Francesca Fioredda, 214587
EFFECTS OF DARATUMUMAB ON THE COMPOSITION AND ACTIVATION STATUS OF IMMUNE-CELL POPULATIONS IN CENTAURUS, A PHASE 2 RANDOMIZED STUDY OF SMOLDERING MULTIPLE MYELOMA (SMM) PATIENTS
EHA Library, Homer Adams III, 214585
MUTANT IDH (MIDH) INHIBITORS, IVOSIDENIB OR ENASIDENIB, WITH AZACITIDINE (AZA) IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML)
EHA Library, Courtney D. DiNardo, 214481
GENOME-WIDE ASSOCIATION STUDY REVEALS ANKYRIN REPEAT AND SOCS BOX PROTEIN 3 (ASB3) AND INOSITOL POLYPHOSPHATE MULTIKINASE (IPMK) AS NEW RISK LOCI FOR RELAPSE IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Library, Laura Hinze, 214578
MS4A3 REGULATES CELL SURFACE CYTOKINE RECEPTOR EXPRESSION, DIFFERENTIATION, AND DRUG RESISTANCE IN CHRONIC MYELOID LEUKEMIA
EHA Library, Anna Eiring, 214572
ENASIDENIB MONOTHERAPY IS EFFECTIVE AND WELL-TOLERATED IN PATIENTS WITH PREVIOUSLY UNTREATED MUTANT-IDH2 (MIDH2) ACUTE MYELOID LEUKEMIA (AML)
EHA Library, Daniel A. Pollyea, 214480
P53 DEFICIENCY DRIVES LEUKEMIC TRANSFORMATION OF HEMATOPOIETIC STEM CELLS BY MAINTAINING QUIESCENCE IN RESPONSE TO DNA DAMAGE
EHA Library, Andreas Brown, 214628
THE EFFECT OF COMPLEMENT INHIBITOR CP40 ON ERYTHROCYTE DESTRUCTION IN AIHA
EHA Library, Inge Baas, 214625
CHARACTERIZATION OF ORALLY BIOAVAILABLE SMALL MOLECULE INHIBITORS OF COMPLEMENT C5
EHA Library, Alonso Ricardo, 214586
EXPRESSION OF PROTEINS IN CD138+ PLASMA CELLS PREDICTS PROGNOSIS IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH VRD REGIMEN.
EHA Library, Irena Misiewicz-Krzeminska, 214584
CLINICAL IMPORTANCE OF DNA METHYLATION SIGNATURES IN CHRONIC LYMPHOCYTIC LEUKAEMIA PATIENTS TREATED WITH CHEMO-IMMUNOTHERAPY
EHA Library, J.C. Strefford, 214580
A NOVEL, INTEGRATED AND VALIDATED PROGNOSTIC INDEX FOR PREDICTING OUTCOME IN ACUTE LYMPHOBLASTIC LEUKAEMIA PROVIDES NEW APPROACH FOR RISK STRATIFICATION.
EHA Library, Anthony Moorman, 214577
A RANDOMIZED PHASE II STUDY OF STANDARD DOSE AZACITIDINE ALONE OR IN COMBINATION WITH LENALIDOMIDE IN HIGH-RISK MDS WITH A KARYOTYPE INCLUDING DEL(5Q)
EHA Library, Bengt Rasmussen, 214575
JAK1-STAT3 SIGNALING AXIS SUPPORTS LEUKEMIC STEM CELL PERSISTENCE IN CML
EHA Library, Mirle Schemionek-Reinders, 214571
SURVIVAL OF VERY ELDERLY PATIENTS WITH DLBCL ACCORDING TO TREATMENT INTENSITY IN THE RITUXIMAB ERA: A SWEDISH LYMPHOMA REGISTRY STUDY
EHA Library, Kristina Sonnevi, 214568
IVOSIDENIB (AG-120) IN MUTANT IDH1 RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA: RESULTS OF A PHASE 1 STUDY
EHA Library, Daniel A. Pollyea, 214479
SPECIFICATION OF HEMATOPOIETIC STEM CELL FATE VIA MODULATION OF MITOCHONDRIAL ACTIVITY
EHA Library, Mukul Girotra, 214627
RED CELL EFFECTS OF THE ANTI-CD47 MONOCLONAL ANTIBODY HU5F9-G4 IN A PHASE I STUDY FOR RELAPSED OR PRIMARY REFRACTORY ACUTE MYELOID LEUKEMIA
EHA Library, Charlotte Brierley, 214624
A COHORT OF 22 PATIENTS WITH SAMD9/SAMD9L DISORDER: BONE MARROW FAILURE AND MDS PREDISPOSITION WITH TRANSIENT MONOSOMY 7
EHA Library, Marie Sébert, 214622
THE CHRONOLOGICAL ORDER OF COPY NUMBER CHANGES IN HYPERDIPLOID MULTIPLE MYELOMA PATIENTS
EHA Library, Francesco Maura, 214620
LINKING ABERRANT CHROMATIN FEATURES IN CHRONIC LYMPHOCYTIC LEUKEMIA TO DEREGULATED TRANSCRIPTION FACTOR NETWORKS
EHA Library, Viola Meyer-Pannwitt, 214579
OUTCOMES OF YOUNG ADULT (≥ 18-25 YEARS) AND PEDIATRIC (<18 YEARS) PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA FOLLOWING TREATMENT WITH CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY
EHA Library, Susana Rives, 214576
A PHASE II CLINICAL TRIAL OF GUADECITABINE (SGI-110) FOR PATIENTS WITH PREVIOUSLY UNTREATED MYELODYSPLASTIC SYNDROME
EHA Library, Guillermo Garcia-Manero, 214574
THE TUMOR SUPPRESSOR MIR-300 PRESERVES CANCER STEM CELLS AND INHIBITS NK CELL ANTICANCER IMMUNITY
EHA Library, Danilo Perrotti, 214570
RADIOTHERAPY TO BULKY AND EXTRALYMPHATIC DISEASE IN COMBINATION WITH 6XR-CHOP-14 OR R-CHOP-21 IN YOUNG GOOD-PROGNOSIS DLBCL PATIENTS: RESULTS OF THE 2X2 RANDOMIZED UNFOLDER TRIAL OF THE DSHNHL/GLA
EHA Library, Viola Pöschel, 214567
INTEGRATED EXPRESSION PROFILING CHARACTERIZES BIOLOGICAL HETEROGENEITY IN REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA AND THE RISK OF RICHTER TRANSFORMATION
EHA Library, Johannes Bloehdorn, 214581
CANDIDATE FDA-APPROVED DRUGS THAT MAY MIMIC HOXA CLUSTER DELETION IN MLL-AF9 LEUKEMIA.
EHA Library, Laura Kettyle, 214634
MUTATIONAL LANDSCAPE OF RELAPSED ACUTE PROMYELOCYTIC LEUKEMIA
EHA Library, Valentina Alfonso, 214635
SINGLE-CELL DNA ANALYSIS OF MUTATIONAL HETEROGENEITY IN ACUTE MYELOID LEUKEMIA TUMORS WITH HIGH-THROUGHPUT DROPLET MICROFLUIDICS
EHA Library, Dennis Eastburn, 214633

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.



{$cookies-google-tag-manager-description}


Save Settings